isosorbide dinitrate ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
NO2 - derivatives 1505 87-33-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • r-isosorbide dinitrate
  • vascardin
  • astridine
  • isosorbide dinitrate
A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.
  • Molecular weight: 236.14
  • Formula: C6H8N2O8
  • CLOGP: -0.08
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 0
  • TPSA: 128.56
  • ALOGS: -2.40
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg O
20 mg oral aerosol
20 mg SL
0.10 g TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.09 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.26 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 22 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.72 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,STK33,SYK,TEK,TTK,ZAP70 50
kinase-selectivity-class AXL,BRAF,CDK9,DDR1,DYRK1B,EPHB4,GRK2,GSK3B,MAP2K6,MAPK7,PRKDC,STK33,SYK,TEK,TTK 15
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Jan. 16, 1968 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiospasm 304.54 11.29 87 25650 3359 90599351
Myocardial infarction 303.96 11.29 247 25490 105725 90496985
Palmoplantar keratoderma 303.03 11.29 87 25650 3420 90599290
Sleep terror 282.31 11.29 87 25650 4377 90598333
Pruritus genital 280.52 11.29 87 25650 4471 90598239
Subarachnoid haemorrhage 277.43 11.29 124 25613 17780 90584930
Carotid artery occlusion 271.84 11.29 92 25645 6250 90596460
Atrial tachycardia 261.10 11.29 88 25649 5902 90596808
Tension headache 245.37 11.29 89 25648 7420 90595290
Anosmia 215.00 11.29 87 25650 9761 90592949
Immunisation 209.67 11.29 59 25678 2154 90600556
Facial pain 190.57 11.29 87 25650 13095 90589615
Ventricular tachycardia 186.30 11.29 105 25632 24603 90578107
Pain of skin 180.02 11.29 89 25648 15993 90586717
Cardiac failure congestive 166.68 11.29 171 25566 98523 90504187
Vasculitis 161.84 11.29 93 25644 22600 90580110
Transient ischaemic attack 161.66 11.29 118 25619 43058 90559652
Muscle twitching 156.28 11.29 93 25644 24109 90578601
Blindness 153.33 11.29 95 25642 26473 90576237
Hallucination 152.61 11.29 136 25601 65823 90536887
Eye pruritus 135.91 11.29 91 25646 28936 90573774
Diplopia 129.61 11.29 88 25649 28626 90574084
Lip swelling 114.79 11.29 92 25645 38518 90564192
Tinnitus 107.96 11.29 93 25644 43009 90559701
Intentional product misuse 99.61 11.29 125 25612 89479 90513231
Disturbance in attention 98.89 11.29 92 25645 47017 90555693
Chest pain 95.56 11.29 251 25486 319394 90283316
Dry skin 93.37 11.29 120 25617 87953 90514757
Blood glucose increased 92.04 11.29 124 25613 95122 90507588
Angioedema 86.02 11.29 99 25638 64777 90537933
Cognitive disorder 85.51 11.29 102 25635 69305 90533405
Visual impairment 84.53 11.29 142 25595 132223 90470487
Rash papular 79.28 11.29 57 25680 20298 90582412
Drug ineffective 75.80 11.29 177 25560 1384121 89218589
Palpitations 72.24 11.29 135 25602 136593 90466117
Dehydration 72.17 11.29 166 25571 194281 90408429
Coronary artery disease 69.28 11.29 65 25672 33558 90569152
Pemphigus 67.87 11.29 7 25730 326857 90275853
Acute myocardial infarction 67.23 11.29 65 25672 34825 90567885
Hyperhidrosis 62.75 11.29 127 25610 136178 90466532
Amnesia 62.19 11.29 111 25626 108394 90494316
Infusion related reaction 61.23 11.29 21 25716 416759 90185951
Heart rate increased 59.03 11.29 111 25626 112791 90489919
Angina pectoris 57.44 11.29 63 25674 39097 90563613
Synovitis 57.12 11.29 12 25725 329740 90272970
Arthropathy 56.36 11.29 17 25720 366225 90236485
Systemic lupus erythematosus 53.55 11.29 18 25719 361878 90240832
Hepatic enzyme increased 53.28 11.29 18 25719 360718 90241992
Maternal exposure during pregnancy 53.12 11.29 18 25719 360045 90242665
Feeling abnormal 52.63 11.29 134 25603 167101 90435609
Glossodynia 51.23 11.29 14 25723 321765 90280945
Hand deformity 50.88 11.29 11 25726 296351 90306359
Contraindicated product administered 50.84 11.29 14 25723 320125 90282585
Vascular stent stenosis 50.57 11.29 15 25722 661 90602049
Treatment failure 48.81 11.29 13 25724 303915 90298795
Bradycardia 48.33 11.29 86 25651 83761 90518949
Cardiac failure 48 11.29 100 25637 109396 90493314
Angina unstable 47.54 11.29 28 25709 7115 90595595
Joint swelling 47.28 11.29 44 25693 503256 90099454
Drug intolerance 44.60 11.29 37 25700 447554 90155156
Anti-cyclic citrullinated peptide antibody positive 44.39 11.29 7 25730 236426 90366284
Therapeutic product effect decreased 44.33 11.29 12 25725 277559 90325151
Tachycardia 44.18 11.29 121 25616 157552 90445158
Dysphoria 43.27 11.29 25 25712 6129 90596581
Haemorrhagic diathesis 43.05 11.29 24 25713 5500 90597210
Generalised bullous fixed drug eruption 40.48 11.29 11 25726 352 90602358
Swelling 37.75 11.29 38 25699 419020 90183690
Hypersensitivity 36.83 11.29 45 25692 454632 90148078
Nasopharyngitis 36.58 11.29 37 25700 407067 90195643
Discomfort 35.10 11.29 17 25720 274318 90328392
Myocardial ischaemia 32.95 11.29 29 25708 13785 90588925
Lower respiratory tract infection 32.89 11.29 15 25722 250644 90352066
COVID-19 32.77 11.29 114 25623 168729 90433981
Duodenal ulcer perforation 32.72 11.29 11 25726 221277 90381433
Dyspnoea 32.38 11.29 387 25350 880568 89722142
Helicobacter infection 32.31 11.29 12 25725 226838 90375872
Muscular weakness 32.17 11.29 130 25607 206536 90396174
Arteriospasm coronary 31.53 11.29 19 25718 5031 90597679
Renal failure 29.47 11.29 93 25644 130914 90471796
Muscle injury 29.42 11.29 7 25730 176647 90426063
Folliculitis 28.78 11.29 11 25726 204342 90398368
Appetite disorder 27.64 11.29 22 25715 9111 90593599
Infection 27.08 11.29 38 25699 362056 90240654
Coronary arterial stent insertion 26.77 11.29 14 25723 2826 90599884
Psoriatic arthropathy 26.50 11.29 16 25721 228319 90374391
Red cell distribution width abnormal 26.32 11.29 7 25730 206 90602504
Wound 25.57 11.29 29 25708 302951 90299759
Shock 25.57 11.29 36 25701 28742 90573968
Haematocrit abnormal 24.91 11.29 10 25727 1097 90601613
Dizziness 23.88 11.29 264 25473 589020 90013690
Back pain 23.86 11.29 163 25574 317012 90285698
Impaired healing 23.75 11.29 19 25718 234180 90368530
Arthritis infective 23.65 11.29 19 25718 7973 90594737
Chronic kidney disease 23.35 11.29 47 25690 50144 90552566
Memory impairment 23.09 11.29 114 25623 197130 90405580
Glomerular filtration rate abnormal 23.03 11.29 10 25727 1335 90601375
BRASH syndrome 22.82 11.29 11 25726 1868 90600842
Mesenteric arterial occlusion 22.58 11.29 6 25731 176 90602534
Loss of consciousness 22.44 11.29 89 25648 140149 90462561
Migraine 22.26 11.29 110 25627 190282 90412428
Exposure during pregnancy 22.16 11.29 21 25716 238389 90364321
Skin warm 22.16 11.29 18 25719 7669 90595041
Irritable bowel syndrome 22.09 11.29 16 25721 207432 90395278
Renal impairment 22.04 11.29 73 25664 105348 90497362
Sinusitis 21.89 11.29 40 25697 343048 90259662
Fibromyalgia 21.85 11.29 16 25721 206253 90396457
Hyperkalaemia 21.40 11.29 53 25684 64911 90537799
Cerebrovascular accident 21.07 11.29 80 25657 123453 90479257
Sinus bradycardia 21.01 11.29 25 25712 16927 90585783
Thinking abnormal 21 11.29 21 25716 11711 90590999
Blood cholesterol increased 20.93 11.29 17 25720 207995 90394715
Off label use 20.64 11.29 207 25530 1102045 89500665
Urticaria 20.36 11.29 36 25701 312698 90290012
Hypotension 20.33 11.29 160 25577 325237 90277473
Drug interaction 20.15 11.29 141 25596 276312 90326398
Paraesthesia 20.00 11.29 25 25712 250301 90352409
Febrile neutropenia 19.96 11.29 10 25727 158339 90444371
Rheumatoid factor positive 19.95 11.29 12 25725 171638 90431072
Blood urea increased 19.88 11.29 33 25704 30380 90572330
Gamma-glutamyltransferase abnormal 19.81 11.29 7 25730 540 90602170
Electrocardiogram ST segment elevation 19.78 11.29 13 25724 4003 90598707
Photophobia 19.48 11.29 27 25710 21242 90581468
Ischaemic cardiomyopathy 19.40 11.29 11 25726 2602 90600108
Therapeutic product effect incomplete 19.32 11.29 16 25721 193880 90408830
Left ventricular hypertrophy 19.02 11.29 15 25722 6129 90596581
Arrhythmia 18.93 11.29 39 25698 42293 90560417
Product use issue 18.86 11.29 41 25696 329878 90272832
Anxiety 18.63 11.29 151 25586 309621 90293089
Blood pressure decreased 18.55 11.29 55 25682 74840 90527870
Stomatitis 18.45 11.29 31 25706 274667 90328043
Liver injury 18.36 11.29 13 25724 170554 90432156
Jugular vein distension 18.31 11.29 8 25729 1085 90601625
Cardiac failure chronic 17.94 11.29 14 25723 5632 90597078
Upper gastrointestinal haemorrhage 17.88 11.29 27 25710 22949 90579761
Acute kidney injury 17.58 11.29 153 25584 320234 90282476
Inflammation 17.47 11.29 15 25722 178577 90424133
Neutropenia 17.41 11.29 23 25714 224881 90377829
Lip erosion 17.35 11.29 8 25729 1230 90601480
N-terminal prohormone brain natriuretic peptide abnormal 17.30 11.29 4 25733 65 90602645
Hypovolaemic shock 17.13 11.29 15 25722 7079 90595631
Mucosal erosion 17.12 11.29 9 25728 1836 90600874
Atrial fibrillation 16.91 11.29 79 25658 133532 90469178
Drug hypersensitivity 16.89 11.29 71 25666 463538 90139172
Blood creatinine increased 16.75 11.29 65 25672 101321 90501389
Gastrointestinal haemorrhage 16.69 11.29 60 25677 90188 90512522
Type 2 diabetes mellitus 16.55 11.29 20 25717 203224 90399486
Weight increased 16.49 11.29 62 25675 417865 90184845
Gynaecomastia 16.40 11.29 5 25732 242 90602468
Insulin C-peptide increased 16.24 11.29 4 25733 86 90602624
Rheumatoid arthritis 16.19 11.29 51 25686 362563 90240147
Rheumatic fever 16.05 11.29 12 25725 153109 90449601
Insomnia 15.65 11.29 154 25583 333320 90269390
Incorrect product administration duration 15.45 11.29 23 25714 19299 90583411
Pseudophaeochromocytoma 15.41 11.29 4 25733 107 90602603
Cardiac disorder 15.27 11.29 43 25694 56829 90545881
Cerebral infarction 14.96 11.29 27 25710 26569 90576141
Liver function test increased 14.86 11.29 3 25734 84852 90517858
Atrioventricular block first degree 14.80 11.29 15 25722 8496 90594214
Coronary artery occlusion 14.74 11.29 15 25722 8539 90594171
Injection site reaction 14.65 11.29 4 25733 92076 90510634
Acidosis 14.51 11.29 18 25719 12718 90589992
Sinus node dysfunction 14.20 11.29 12 25725 5400 90597310
Condition aggravated 14.15 11.29 105 25632 595440 90007270
International normalised ratio increased 13.93 11.29 37 25700 47279 90555431
Orthopnoea 13.67 11.29 13 25724 6822 90595888
Respiratory acidosis 13.56 11.29 14 25723 8105 90594605
Acute coronary syndrome 13.49 11.29 16 25721 10797 90591913
Hepatic function abnormal 13.42 11.29 36 25701 46252 90556458
Genital erosion 13.32 11.29 5 25732 458 90602252
Syncope 12.99 11.29 73 25664 132590 90470120
Bursitis 12.94 11.29 11 25726 131643 90471067
Blood potassium increased 12.88 11.29 22 25715 20727 90581983
Breast cancer stage III 12.83 11.29 4 25733 84443 90518267
C-reactive protein increased 12.61 11.29 20 25717 181369 90421341
General physical health deterioration 12.54 11.29 55 25682 355060 90247650
Pulseless electrical activity 12.46 11.29 14 25723 8918 90593792
Coronary artery stenosis 12.45 11.29 11 25726 5255 90597455
Peripheral vascular disorder 12.42 11.29 12 25725 6419 90596291
Epilepsy 12.30 11.29 4 25733 82202 90520508
Depressed level of consciousness 12.29 11.29 47 25690 72737 90529973
Oral pain 12.21 11.29 28 25709 32655 90570055
Rhabdomyolysis 12.08 11.29 37 25700 51219 90551491
Haemorrhage subcutaneous 12.07 11.29 9 25728 3387 90599323
Intestinal obstruction 11.92 11.29 30 25707 37101 90565609
Conjunctival cyst 11.79 11.29 3 25734 74 90602636
Hepatic atrophy 11.64 11.29 4 25733 284 90602426
Vomiting 11.51 11.29 299 25438 787994 89814716
Disseminated cytomegaloviral infection 11.47 11.29 4 25733 297 90602413

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myocardial infarction 243.48 14.41 322 23477 123687 42473849
Cardiospasm 241.03 14.41 74 23725 1833 42595703
Palmoplantar keratoderma 220.72 14.41 72 23727 2182 42595354
Pruritus genital 209.59 14.41 72 23727 2567 42594969
Sleep terror 202.31 14.41 72 23727 2854 42594682
Tension headache 198.77 14.41 74 23725 3340 42594196
Atrial tachycardia 195.38 14.41 77 23722 4063 42593473
Facial pain 186.31 14.41 75 23724 4185 42593351
Cardiac failure congestive 184.60 14.41 233 23566 85369 42512167
Carotid artery occlusion 183.98 14.41 74 23725 4120 42593416
Anosmia 168.96 14.41 74 23725 5102 42592434
Immunisation 159.76 14.41 49 23750 1209 42596327
Chest pain 145.51 14.41 271 23528 139259 42458277
Pain of skin 132.05 14.41 72 23727 8008 42589528
Ventricular tachycardia 119.14 14.41 113 23686 30047 42567489
Subarachnoid haemorrhage 118.53 14.41 83 23716 14389 42583147
Muscle twitching 114.21 14.41 75 23724 11705 42585831
Pericarditis 109.86 14.41 77 23722 13367 42584169
Eye pruritus 104.22 14.41 70 23729 11342 42586194
Blindness 102.48 14.41 83 23716 17895 42579641
Lip swelling 98.26 14.41 83 23716 18970 42578566
Drug ineffective 96.54 14.41 127 23672 630070 41967466
Vasculitis 94.59 14.41 80 23719 18314 42579222
Transient ischaemic attack 89.27 14.41 102 23697 33637 42563899
Diplopia 85.76 14.41 79 23720 20237 42577299
Acute myocardial infarction 84.38 14.41 131 23668 58034 42539502
Amnesia 83.87 14.41 91 23708 28346 42569190
Rash papular 79.14 14.41 60 23739 11751 42585785
Tinnitus 69.07 14.41 83 23716 28855 42568681
Disturbance in attention 68.58 14.41 84 23715 29782 42567754
Angina unstable 67.67 14.41 54 23745 11394 42586142
Coronary artery disease 63.07 14.41 110 23689 53610 42543926
Blood glucose increased 62.01 14.41 131 23668 73568 42523968
Migraine 60.83 14.41 73 23726 25341 42572195
Angina pectoris 60.64 14.41 83 23716 32813 42564723
Alopecia 60.31 14.41 78 23721 29198 42568338
Feeling abnormal 59.82 14.41 125 23674 69661 42527875
Angioedema 59.26 14.41 94 23705 42383 42555153
Cognitive disorder 56.72 14.41 82 23717 34090 42563446
Off label use 56.22 14.41 177 23622 638158 41959378
Dizziness 53.92 14.41 278 23521 248976 42348560
Palpitations 51.97 14.41 98 23701 50699 42546837
Dry skin 51.63 14.41 95 23704 48243 42549293
Hallucination 50.44 14.41 104 23695 57403 42540133
Visual impairment 50.23 14.41 88 23711 43025 42554511
Silent myocardial infarction 48.71 14.41 15 23784 375 42597161
Heart rate increased 48.71 14.41 98 23701 53157 42544379
Myocardial ischaemia 47.47 14.41 54 23745 17708 42579828
Cardiac failure 45.37 14.41 147 23652 106709 42490827
Dehydration 41.60 14.41 173 23626 141594 42455942
Abdominal discomfort 40.91 14.41 113 23686 75142 42522394
Memory impairment 40.76 14.41 88 23711 50134 42547402
Hyperhidrosis 40.68 14.41 127 23672 90385 42507151
Toxic epidermal necrolysis 38.41 14.41 60 23739 26690 42570846
Bradycardia 37.55 14.41 119 23680 85365 42512171
Febrile neutropenia 36.60 14.41 30 23769 185673 42411863
Muscular weakness 34.65 14.41 114 23685 83384 42514152
Dyspnoea 34.11 14.41 387 23412 442234 42155302
Oral mucosal eruption 31.91 14.41 11 23788 396 42597140
Neutropenia 31.55 14.41 39 23760 199392 42398144
Hypotension 29.52 14.41 245 23554 257386 42340150
Product use in unapproved indication 29.25 14.41 36 23763 184420 42413116
Toxicity to various agents 29.25 14.41 52 23747 229084 42368452
Malaise 28.29 14.41 209 23590 211947 42385589
Syncope 28.11 14.41 120 23679 99286 42498250
Hypoglycaemia 27.82 14.41 85 23714 59769 42537767
Cutaneous lupus erythematosus 27.29 14.41 12 23787 834 42596702
Peripheral swelling 27.11 14.41 111 23688 90159 42507377
Abdominal pain upper 26.75 14.41 104 23695 82505 42515031
Coronary artery occlusion 25.35 14.41 31 23768 10966 42586570
Prinzmetal angina 24.71 14.41 13 23786 1344 42596192
Anxiety 24.02 14.41 130 23669 118430 42479106
Drug intolerance 23.14 14.41 8 23791 80416 42517120
Drug abuse 23.13 14.41 15 23784 104756 42492780
Bleeding time prolonged 23.12 14.41 10 23789 668 42596868
Back pain 21.41 14.41 144 23655 141632 42455904
Pruritus 21.31 14.41 179 23620 188592 42408944
Craniocerebral injury 20.37 14.41 17 23782 3817 42593719
Insomnia 20.24 14.41 124 23675 118129 42479407
Intentional product misuse 20.09 14.41 78 23721 61822 42535714
Pulmonary oedema 19.69 14.41 70 23729 53202 42544334
Disease progression 18.86 14.41 32 23767 143624 42453912
Chronic kidney disease 17.39 14.41 62 23737 47179 42550357
Malignant neoplasm progression 17.33 14.41 21 23778 108379 42489157
Occult blood positive 16.89 14.41 16 23783 4241 42593295
Drug interaction 16.81 14.41 225 23574 266774 42330762
Condition aggravated 16.61 14.41 82 23717 260672 42336864
Coronary artery stenosis 15.91 14.41 24 23775 10355 42587181
Therapeutic product effect incomplete 15.86 14.41 10 23789 70929 42526607
Cytokine release syndrome 15.53 14.41 3 23796 44524 42553012
Normochromic normocytic anaemia 15.46 14.41 22 23777 9009 42588527
Arteriospasm coronary 15.44 14.41 16 23783 4722 42592814
Tachycardia 15.44 14.41 103 23696 100984 42496552
Pancytopenia 14.75 14.41 27 23772 117716 42479820
Ischaemia 14.61 14.41 16 23783 5031 42592505
Coronary artery restenosis 14.46 14.41 8 23791 914 42596622

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myocardial infarction 540.71 11.66 512 43460 191571 110353756
Cardiospasm 523.49 11.66 155 43817 4812 110540515
Palmoplantar keratoderma 502.52 11.66 153 43819 5234 110540093
Pruritus genital 473.71 11.66 153 43819 6369 110538958
Sleep terror 471.70 11.66 153 43819 6457 110538870
Atrial tachycardia 445.05 11.66 159 43813 9019 110536308
Carotid artery occlusion 434.90 11.66 158 43814 9407 110535920
Tension headache 426.61 11.66 156 43816 9462 110535865
Anosmia 383.76 11.66 155 43817 12317 110533010
Subarachnoid haemorrhage 378.09 11.66 200 43772 29502 110515825
Facial pain 359.31 11.66 157 43815 15182 110530145
Immunisation 351.50 11.66 103 43869 3080 110542247
Cardiac failure congestive 342.27 11.66 358 43614 150642 110394685
Pain of skin 313.33 11.66 155 43817 19874 110525453
Ventricular tachycardia 288.89 11.66 203 43769 49806 110495521
Muscle twitching 270.50 11.66 161 43811 29774 110515553
Blindness 258.80 11.66 168 43804 36191 110509136
Vasculitis 251.03 11.66 164 43808 35709 110509618
Eye pruritus 239.57 11.66 154 43818 32621 110512706
Transient ischaemic attack 238.19 11.66 200 43772 63782 110481545
Diplopia 218.86 11.66 160 43812 41734 110503593
Lip swelling 206.60 11.66 167 43805 50500 110494827
Hallucination 199.05 11.66 223 43749 101209 110444118
Chest pain 182.97 11.66 438 43534 375937 110169390
Disturbance in attention 181.23 11.66 169 43803 61826 110483501
Tinnitus 178.84 11.66 166 43806 60374 110484953
Blood glucose increased 167.96 11.66 234 43738 132262 110413065
Rash papular 159.12 11.66 112 43860 27527 110517800
Acute myocardial infarction 153.86 11.66 178 43794 83599 110461728
Drug ineffective 150.05 11.66 234 43738 1520306 109025021
Dry skin 148.34 11.66 198 43774 107455 110437872
Angioedema 143.19 11.66 186 43786 98314 110447013
Cognitive disorder 142.70 11.66 175 43797 87336 110457991
Amnesia 136.32 11.66 188 43784 105220 110440107
Visual impairment 133.84 11.66 212 43760 134216 110411111
Coronary artery disease 126.10 11.66 149 43823 71541 110473786
Angina unstable 119.54 11.66 77 43895 16355 110528972
Dehydration 117.53 11.66 308 43664 279203 110266124
Intentional product misuse 113.99 11.66 196 43776 132708 110412619
Hyperhidrosis 113.30 11.66 238 43734 187060 110358267
Heart rate increased 106.56 11.66 199 43773 143635 110401692
Palpitations 104.17 11.66 209 43763 159003 110386324
Feeling abnormal 98.28 11.66 220 43752 180491 110364836
Bradycardia 87.57 11.66 192 43780 155325 110390002
Myocardial ischaemia 86.28 11.66 77 43895 26607 110518720
Angina pectoris 83.37 11.66 113 43859 62182 110483145
Cardiac failure 81.11 11.66 209 43763 187417 110357910
Infusion related reaction 79.90 11.66 26 43946 381136 110164191
Treatment failure 73.99 11.66 11 43961 277223 110268104
Synovitis 72.87 11.66 11 43961 274081 110271246
Drug intolerance 67.36 11.66 39 43933 406473 110138854
Arthropathy 65.03 11.66 17 43955 287505 110257822
Joint swelling 63.32 11.66 50 43922 442795 110102532
Muscular weakness 62.50 11.66 229 43743 248239 110297088
Dizziness 62.02 11.66 482 43490 697711 109847616
Tachycardia 59.65 11.66 212 43760 226433 110318894
Off label use 58.99 11.66 353 43619 1499832 109045495
Pemphigus 58.45 11.66 8 43964 214562 110330765
Hepatic enzyme increased 57.24 11.66 28 43944 320864 110224463
Silent myocardial infarction 56.81 11.66 18 43954 703 110544624
Migraine 55.35 11.66 172 43800 171480 110373847
Hand deformity 55.33 11.66 10 43962 218496 110326831
Swelling 54.92 11.66 36 43936 351005 110194322
Nasopharyngitis 54.53 11.66 46 43926 394315 110151012
Systemic lupus erythematosus 53.90 11.66 17 43955 254321 110291006
Maternal exposure during pregnancy 52.32 11.66 18 43954 254865 110290462
Anti-cyclic citrullinated peptide antibody positive 51.47 11.66 6 43966 181978 110363349
Lower respiratory tract infection 50.19 11.66 17 43955 243089 110302238
Dyspnoea 50.18 11.66 665 43307 1106207 109439120
Therapeutic product effect decreased 48.87 11.66 18 43954 244298 110301029
Memory impairment 47.41 11.66 179 43793 196765 110348562
Hypotension 45.54 11.66 360 43612 523489 110021838
Syncope 45.42 11.66 180 43792 202356 110342971
Toxic epidermal necrolysis 45.15 11.66 81 43891 56646 110488681
Glossodynia 45.01 11.66 16 43956 221988 110323339
Back pain 44.61 11.66 276 43696 370720 110174607
Febrile neutropenia 43.72 11.66 37 43935 316730 110228597
Arteriospasm coronary 43.58 11.66 33 43939 9067 110536260
Contraindicated product administered 42.28 11.66 23 43949 248244 110297083
Anxiety 41.03 11.66 256 43716 344822 110200505
Drug interaction 40.36 11.66 338 43634 499845 110045482
Neutropenia 40.27 11.66 54 43918 374566 110170761
Duodenal ulcer perforation 39.24 11.66 11 43961 177689 110367638
Hypoglycaemia 38.03 11.66 117 43855 115987 110429340
Hypersensitivity 37.85 11.66 64 43908 403934 110141393
Renal failure 37.59 11.66 184 43788 226390 110318937
Psoriatic arthropathy 36.89 11.66 16 43956 196745 110348582
Coronary artery occlusion 36.74 11.66 38 43934 15734 110529593
Folliculitis 35.88 11.66 11 43961 167642 110377685
Helicobacter infection 35.37 11.66 14 43958 181863 110363464
COVID-19 35.09 11.66 191 43781 244869 110300458
Discomfort 34.97 11.66 21 43951 214686 110330641
Therapeutic product effect incomplete 34.92 11.66 23 43949 223782 110321545
Product use in unapproved indication 34.87 11.66 79 43893 447298 110098029
Prinzmetal angina 33.82 11.66 17 43955 2252 110543075
Impaired healing 33.82 11.66 18 43954 196699 110348628
Insomnia 32.50 11.66 250 43722 360340 110184987
Dysphoria 32.31 11.66 24 43948 6404 110538923
Gastrointestinal haemorrhage 32.31 11.66 141 43831 165377 110379950
Blood urea increased 32.22 11.66 69 43903 54888 110490439
Condition aggravated 31.94 11.66 167 43805 734669 109810658
Rheumatoid arthritis 31.37 11.66 44 43928 299569 110245758
Irritable bowel syndrome 31.34 11.66 13 43959 164202 110381125
Haemorrhagic diathesis 31.12 11.66 25 43947 7483 110537844
Acute coronary syndrome 31.03 11.66 42 43930 23070 110522257
Muscle injury 30.56 11.66 9 43963 140798 110404529
Fibromyalgia 30.33 11.66 15 43957 170894 110374433
Rhabdomyolysis 29.43 11.66 110 43862 120291 110425036
Chronic kidney disease 28.92 11.66 81 43891 76210 110469117
Weight increased 28.88 11.66 79 43893 419565 110125762
Generalised bullous fixed drug eruption 28.24 11.66 11 43961 793 110544534
Stomatitis 27.98 11.66 40 43932 270202 110275125
Sinusitis 27.77 11.66 47 43925 296641 110248686
Pericarditis 27.57 11.66 165 43807 218949 110326378
Hyperkalaemia 27.52 11.66 117 43855 135679 110409648
Oral mucosal eruption 27.40 11.66 12 43960 1165 110544162
Infection 27.38 11.66 65 43907 362135 110183192
Coronary arterial stent insertion 27.33 11.66 21 43951 5894 110539433
Wound 27.05 11.66 32 43940 234405 110310922
Drug hypersensitivity 26.61 11.66 92 43880 453998 110091329
Coronary artery stenosis 26.53 11.66 30 43942 13728 110531599
Cardiac failure chronic 26.44 11.66 30 43942 13781 110531546
Cerebrovascular accident 26.42 11.66 142 43830 181142 110364185
Blood creatinine increased 25.80 11.66 142 43830 182747 110362580
Ischaemic cardiomyopathy 25.66 11.66 23 43949 7988 110537339
Pruritus 25.23 11.66 347 43625 581213 109964114
Atrial fibrillation 25.20 11.66 167 43805 229475 110315852
Product use issue 25.13 11.66 54 43918 311641 110233686
Occult blood positive 25.09 11.66 22 43950 7423 110537904
General physical health deterioration 25.03 11.66 86 43886 425209 110120118
Inflammation 24.94 11.66 24 43948 193214 110352113
Rheumatoid factor positive 24.20 11.66 11 43961 131629 110413698
Pulmonary oedema 23.80 11.66 91 43881 100568 110444759
Blood cholesterol increased 23.79 11.66 23 43949 184762 110360565
Bursitis 23.66 11.66 11 43961 129907 110415420
C-reactive protein abnormal 23.59 11.66 11 43961 129684 110415643
International normalised ratio increased 23.52 11.66 82 43890 86690 110458637
Musculoskeletal stiffness 22.95 11.66 48 43924 279774 110265553
Exposure during pregnancy 22.54 11.66 20 43952 167404 110377923
Lung disorder 22.50 11.66 23 43949 180024 110365303
Dry mouth 22.31 11.66 28 43944 199920 110345407
Loss of consciousness 22.29 11.66 144 43828 196162 110349165
Red cell distribution width abnormal 21.95 11.66 7 43965 279 110545048
Urticaria 21.95 11.66 60 43912 318797 110226530
Type 2 diabetes mellitus 21.74 11.66 23 43949 177209 110368118
Abdominal pain upper 21.61 11.66 223 43749 348888 110196439
Drug ineffective for unapproved indication 21.55 11.66 7 43965 102831 110442496
Liver injury 21.44 11.66 17 43955 150396 110394931
Rheumatic fever 21.38 11.66 11 43961 122568 110422759
Ischaemia 21.37 11.66 22 43950 9061 110536266
Cardiac failure acute 21.26 11.66 36 43936 24042 110521285
Electrocardiogram ST segment elevation 21.21 11.66 22 43950 9138 110536189
Blood pressure decreased 20.92 11.66 96 43876 114995 110430332
Atrioventricular block first degree 20.87 11.66 27 43945 14198 110531129
Cardiac disorder 20.60 11.66 72 43900 76208 110469119
Night sweats 20.58 11.66 14 43958 133969 110411358
Arthritis 20.28 11.66 22 43950 167564 110377763
Bleeding time prolonged 20.13 11.66 10 43962 1292 110544035
Sleep disorder 19.97 11.66 30 43942 198614 110346713
Cutaneous lupus erythematosus 19.76 11.66 14 43958 3474 110541853
Inappropriate schedule of product administration 19.29 11.66 32 43940 203605 110341722
Breast cancer stage III 19.22 11.66 4 43968 79113 110466214
Neuropathy peripheral 19.08 11.66 26 43946 179251 110366076
Musculoskeletal pain 19.03 11.66 27 43945 182996 110362331
Epilepsy 19.01 11.66 8 43964 100201 110445126
Injection site reaction 18.77 11.66 6 43966 89064 110456263
Mesenteric arterial occlusion 18.16 11.66 6 43966 268 110545059
Normochromic normocytic anaemia 17.94 11.66 24 43948 13033 110532294
Gastrointestinal disorder 17.82 11.66 44 43928 241908 110303419
Mucosal inflammation 17.73 11.66 8 43964 96133 110449194
Shock 17.54 11.66 54 43918 53534 110491793
Peripheral vascular disorder 17.05 11.66 19 43953 8557 110536770
Toxicity to various agents 16.75 11.66 117 43855 480438 110064889
Cerebral infarction 16.74 11.66 52 43920 51786 110493541
Appetite disorder 16.66 11.66 20 43952 9749 110535578
Atrioventricular block complete 16.39 11.66 29 43943 20053 110525274
Sleep disorder due to general medical condition, insomnia type 16.28 11.66 11 43961 105632 110439695
Paraesthesia 16.20 11.66 56 43916 276465 110268862
Malaise 16.18 11.66 365 43607 671454 109873873
Pulseless electrical activity 16.07 11.66 26 43946 16731 110528596
Upper gastrointestinal haemorrhage 15.95 11.66 50 43922 50046 110495281
Asthma 15.83 11.66 49 43923 250242 110295085
Drug abuse 15.78 11.66 29 43943 177382 110367945
Arrhythmia 15.71 11.66 62 43910 69513 110475814
Cardio-respiratory arrest 15.71 11.66 89 43883 115747 110429580
Ill-defined disorder 15.46 11.66 24 43948 156829 110388498
Dyspepsia 15.45 11.66 33 43939 190932 110354395
Jugular vein distension 15.40 11.66 9 43963 1607 110543720
Liver function test increased 15.36 11.66 8 43964 88540 110456787
Renal hypoplasia 15.29 11.66 3 43969 14 110545313
Hepatic function abnormal 15.14 11.66 73 43899 89222 110456105
Facet joint syndrome 15.03 11.66 10 43962 96818 110448509
Haematocrit abnormal 14.82 11.66 9 43963 1724 110543603
Left ventricular hypertrophy 14.72 11.66 22 43950 13222 110532105
Arterial injury 14.68 11.66 7 43965 827 110544500
Lip dry 14.66 11.66 11 43961 100072 110445255
Sinus node dysfunction 14.58 11.66 18 43954 9029 110536298
Skin warm 14.39 11.66 18 43954 9152 110536175
Cytokine release syndrome 14.36 11.66 5 43967 70301 110475026
Myelosuppression 14.30 11.66 10 43962 94330 110450997
Pulmonary embolism 14.27 11.66 41 43931 214433 110330894
Gamma-glutamyltransferase abnormal 13.98 11.66 7 43965 920 110544407
Renal impairment 13.93 11.66 125 43847 188320 110357007
Nail disorder 13.93 11.66 3 43969 57932 110487395
Obesity 13.58 11.66 15 43957 113336 110431991
Photophobia 13.57 11.66 31 43941 25740 110519587
Flushing 13.52 11.66 13 43959 104723 110440604
Pseudophaeochromocytoma 13.30 11.66 4 43968 131 110545196
Vascular stent stenosis 13.23 11.66 8 43964 1521 110543806
Abdominal discomfort 13.19 11.66 225 43747 393633 110151694
Sinus bradycardia 12.88 11.66 33 43939 29450 110515877
Blepharospasm 12.86 11.66 3 43969 54848 110490479
Ephelides 12.81 11.66 4 43968 149 110545178
Pulmonary fibrosis 12.79 11.66 13 43959 102029 110443298
Peripheral venous disease 12.64 11.66 9 43963 84108 110461219
Joint range of motion decreased 12.63 11.66 18 43954 121814 110423513
Injection site pain 12.60 11.66 33 43939 177889 110367438
Arthritis infective 12.57 11.66 18 43954 10411 110534916
BRASH syndrome 12.54 11.66 11 43961 3712 110541615
Swollen joint count increased 12.51 11.66 9 43963 83652 110461675
Live birth 12.47 11.66 6 43966 69478 110475849
Supraventricular tachycardia 12.44 11.66 29 43943 24393 110520934
Serotonin syndrome 12.44 11.66 4 43968 59149 110486178
Stevens-Johnson syndrome 12.43 11.66 44 43928 46857 110498470
Wound infection 12.42 11.66 12 43960 96453 110448874
Adverse drug reaction 12.32 11.66 78 43894 105481 110439846
Coronary artery restenosis 12.32 11.66 7 43965 1185 110544142
Incorrect product administration duration 12.32 11.66 26 43946 20472 110524855
Glomerular filtration rate abnormal 12.21 11.66 9 43963 2374 110542953
C-reactive protein increased 12.18 11.66 45 43927 217874 110327453
Therapy non-responder 12.06 11.66 28 43944 157279 110388048
Myopathy 12.03 11.66 29 43943 24931 110520396
Disease progression 12.00 11.66 53 43919 243981 110301346
Malignant neoplasm progression 11.89 11.66 33 43939 174534 110370793
Gastrointestinal tract mucosal pigmentation 11.87 11.66 7 43965 1270 110544057
Hypovolaemic shock 11.83 11.66 21 43951 14562 110530765
Orthopnoea 11.82 11.66 18 43954 11003 110534324
Leukopenia 11.80 11.66 26 43946 148765 110396562
Lip erosion 11.77 11.66 8 43964 1858 110543469

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01DA08 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
VASODILATORS USED IN CARDIAC DISEASES
Organic nitrates
ATC C01DA58 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
VASODILATORS USED IN CARDIAC DISEASES
Organic nitrates
ATC C05AE02 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Muscle relaxants
FDA CS M0014874 Nitrates
FDA PE N0000009909 Vasodilation
FDA EPC N0000175415 Nitrate Vasodilator
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents
MeSH PA D020030 Nitric Oxide Donors
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:50566 nitric oxide donor

Related Drugs by ATC class:

C01DA Organic nitrates 7 drugs
C05AE Muscle relaxants 2 drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic heart failure indication 48447003
Angina pectoris indication 194828000
Angina Pectoris Prevention indication
Prevention of Bleeding Esophageal Varices off-label use
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Hyperthyroidism contraindication 34486009 DOID:7998
Low blood pressure contraindication 45007003
Benign intracranial hypertension contraindication 68267002 DOID:11459
Injury of head contraindication 82271004
Increased intestinal motility contraindication 102624003
Cerebrovascular accident contraindication 230690007
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Lupus erythematosus and erythema multiforme-like syndrome contraindication 238926009
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Slow acetylator due to N-acetyltransferase enzyme variant contraindication 425079005
Malabsorption States contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Soluble guanylate cyclase Enzyme ACTIVATOR CHEMBL CHEMBL
Atrial natriuretic peptide receptor 1 Enzyme WOMBAT-PK

External reference:

IDSource
4017825 VUID
N0000146183 NUI
D00516 KEGG_DRUG
4017825 VANDF
C0022252 UMLSCUI
CHEBI:6061 CHEBI
CHEMBL6622 ChEMBL_ID
D007548 MESH_DESCRIPTOR_UI
DB00883 DRUGBANK_ID
7051 IUPHAR_LIGAND_ID
996 INN_ID
IA7306519N UNII
6883 PUBCHEM_CID
379630 RXNORM
2988 MMSL
2996 MMSL
4934 MMSL
d00268 MMSL
000688 NDDF
387332007 SNOMEDCT_US
5924003 SNOMEDCT_US
IA7306519N INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1765 TABLET 2.50 mg SUBLINGUAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1767 TABLET 5 mg SUBLINGUAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1769 TABLET 5 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1771 TABLET 10 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0143-1772 TABLET 20 mg ORAL ANDA 21 sections
ISOSORBIDE DINITRATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8463 TABLET 10 mg ORAL ANDA 21 sections
ISOSORBIDE DINITRATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8464 TABLET 20 mg ORAL ANDA 21 sections
ISOSORBIDE DINITRATE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8465 TABLET 30 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1556 TABLET 10 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1556 TABLET 10 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1635 TABLET 5 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1635 TABLET 5 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1695 TABLET 20 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0781-1695 TABLET 20 mg ORAL ANDA 23 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6619 TABLET 10 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6620 TABLET 20 mg ORAL ANDA 21 sections
Isosorbide dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 16714-007 TABLET 5 mg ORAL ANDA 17 sections
Isosorbide dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 16714-008 TABLET 10 mg ORAL ANDA 17 sections
Isosorbide dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 16714-009 TABLET 20 mg ORAL ANDA 17 sections
Isosorbide dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 16714-010 TABLET 30 mg ORAL ANDA 17 sections
BiDil Human Prescription Drug Label 2 24338-010 TABLET, FILM COATED 20 mg ORAL NDA 29 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 49884-009 TABLET 30 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 49884-020 TABLET 5 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 49884-021 TABLET 10 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 49884-022 TABLET 20 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 49884-556 TABLET 40 mg ORAL ANDA 19 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 50268-447 TABLET 5 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 50268-447 TABLET 5 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 50268-448 TABLET 10 mg ORAL ANDA 21 sections
Isosorbide Dinitrate HUMAN PRESCRIPTION DRUG LABEL 1 50268-448 TABLET 10 mg ORAL ANDA 21 sections